BVT 2733

• Description :

  BVT 2733 is a potent, selective, and orally active non-steroidal 11β-hydroxydehydrogenase 1 (11β-HSD1) inhibitor. BVT 2733 is potently against the mouse enzyme (IC50=96 nM) over the human enzyme (IC50=3341 nM) . BVT 2733 has the potential for the study of arthritis and obesity related disease[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  11β-HSD

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/BVT-2733.html

• Purity :

  99.24

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  ClC1=C(C)C(S(NC2=NC(CC(N3CCN(C)CC3)=O)=CS2)(=O)=O)=CC=C1

• Molecular Formula :

  C17H21ClN4O3S2

• Molecular Weight :

  428.96

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Zhang L, et al. 11β-Hydroxysteroid dehydrogenase 1 inhibition attenuates collagen-induced arthritis. Int Immunopharmacol. 2013 Nov;17 (3) :489-94.|[2]Wang L, et al. BVT.2733, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, attenuates obesity and inflammation in diet-induced obese mice. PLoS One. 2012;7 (7) :e40056.|[3]11β-hydroxydehydrogenase 1 (11β-HSD1) Inhibitor in Development

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• CAS Number :

  [376640-41-4]